In this study, we investigated the role of miR-322 in hypoxia-induced cellular responses in rat PASMCs. We provide evidence that HIF-1α, but not HIF-2α, upregulates the transcription of miR-322 and that miR-322 may modulate proliferation and migration of PASMCs via the BMP-Smad pathway.

Antibe Therapeutics Inc. (TSX:ATE.V) originates, develops and out-licenses patent-protected new pharmaceuticals that are improved versions of existing drugs. These improvements are based on Nobel Prize-winning medical research highlighting the crucial role of gaseous mediators, chemical substances produced in the human body to regulate a range of fundamental cellular processes. The Corporation’s drug design methodologies involve chemically linking an existing off-patent drug (“base drug”) to an Antibe-patented, hydrogen sulfide-releasing molecule. For medical conditions characterized by inflammation, pain or vascular dysfunction, the Corporation’s methodologies can efficiently produce improved versions of a number of existing drugs. Notably, Antibe’s products are themselves fully patent-protectable and may benefit from the predictable toxicity and effectiveness profiles of the base drug.

We have entered into the Samil Agreement for the commercialization of Aramchol in Korea. Under the terms of the Samil Agreement, we have received upfront and milestone payments of $3.6 million, and may be eligible to receive up to approximately $4.5 million in additional payments for development and regulatory milestones for Aramchol in the licensed territories.

        The Company has derived all of its revenue to date from its collaboration agreement with Merck (the "Merck Agreement"). Refer to Note 7, "Revenue Recognition." The Merck Agreement is accounted for under ASC 606 since it does not represent a collaborative arrangement under ASC 808, "Collaborative Arrangements," as the Company is not an active participant and is not exposed to significant risks and rewards of the arrangement.

As a “foreign private issuer,” we are subject to the information reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under those requirements file reports with the SEC. Those other reports or other information may be inspected without charge at the locations described above. As a “foreign private issuer,” we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders will be exempt from the reporting and “short-swing” profit recovery provisions contained in Section 16 of the Exchange Act with respect to their purchases and sales of ordinary shares. Furthermore, as a “foreign private issuer,” we are also not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act.

Forgot about Godel. Good friends with Einstein. Studied Kant and Husserl, a phenomenologist, believed in God and wrote an ontological proof of God. I never could comprehend one single word of his incompleteness theorem. Not a word.

        General and administrative expenses increased by $4.7 million to $14.5 million for the year ended December 31, 2018, from $9.8 million for the year ended December 31, 2017. This was primarily attributable to $1.7 million increase in compensation, benefits and other employee-related expenses due to 2018 salary increases and higher average headcount to support our increased activities; a $1.1 million

Thanks also for your comments on the extracts of magnolia, I am thinking of using it instead of Berberine for glucose control. I am also interested in its potential for adipogenesis (the subcutaneous, anti inflammatory kind). The only thing that remains as a question mark in my mind is the fact that honokiol can protect mitochondria, but also increase membrane permeability and cause apoptosis in cancer cells (via the transition pore). Here is the relevant study.

cAMP levels were determined by a cAMP immunoassay kit according to the manufacturer’s protocol (Enzo Life Science). NK cells were preincubated with 0.5 mM isobutylmethylxanthine, a phosphodiesterase inhibitor. After incubation with PME for the indicated times, the cells were lysed in 0.1 M HCl to stop the reaction. After centrifugation at 20,000 × g for 10 min at 4°C, supernatants were collected and acetylated, and immunoassays were performed.

Ritchie, R. H. & Delbridge, L. M. Cardiac hypertrophy, substrate utilization and metabolic remodelling: cause or effect ?  Clin. Exp. Pharmacol. Physiol. 33, 159–166, 10.1111/j.1440-1681.2006.04342.x (2006).

One thing that should give us hope, is that the centenarians and super centenarians were NOT in good health, they just had the right genes to limp on with a large senescent cell burden and huge fused mitochondria. We will hopefully be preventing these accumulations so we should be at minimum very healthy until near the point when we die, and then depending on our genetics we’ll then limp on too, or quickly succumb. It’s hard to say what age that would be but I’d be surprised if it’s younger than 90 for an average person without any particularly bad (APOE4) or good (FOXO3) genes. And then like Aldebaran says, we’re only 10 years from very effective senolytics treatment (or sooner if you travel abroad but take the risk with it being unregulated). I’d say the time scales for telomerase therapy and maybe epigenetic reprogramming are not that much further out.

Our competitors currently include companies with marketed products and/or advanced clinical programs. The majority of our competitors include, but are not limited to, Intercept Pharmaceuticals, Inc., Genfit S.A., Gilead Sciences, Inc., Allergan, Plc., Madrigal Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., Novartis, CymaBay Therapeutics and Viking Therapeutics among others. See also “Item 4. Information on the Company—Competition.” Moreover, several additional companies have reported the commencement of research projects and proof-of-concept trials related to NASH, including those mentioned in the preceding sentence.